Last Price
33.20
Today's Change
+0.34 (1.03%)
Day's Change
31.22 - 33.31
Trading Volume
1,353,788
Market Cap
2 Billion
Shares Outstanding
66 Million
Avg Volume
964,546
Avg Price (50 Days)
38.34
Avg Price (200 Days)
38.87
PE Ratio
-12.07
EPS
-2.75
Earnings Announcement
31-Oct-2024
Previous Close
32.86
Open
32.20
Day's Range
31.22 - 33.315
Year Range
22.11 - 53.18
Trading Volume
1,353,788
1 Day Change
1.03%
5 Day Change
-19.28%
1 Month Change
-13.02%
3 Month Change
-11.91%
6 Month Change
-20.56%
Ytd Change
-17.84%
1 Year Change
21.43%
3 Year Change
-39.65%
5 Year Change
1429.95%
10 Year Change
-83.83%
Max Change
-96.22%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.